YOLFTbeta
Ovid Therapeutics Inc

Ovid Therapeutics Inc

OVID · NASDAQ · Healthcare / Biotechnology

2.54USD-0.01 (-0.39%)

Price History

Full chart

Market Stats

Previous Close2.55
Open2.50
Day Range2.33 – 2.56
52-Week Range1.18 – 3.11
Volume2.90M
Market Cap468.71M
P/E (TTM)0.00
Forward P/E1.79
EPS-0.21
Dividend Yield0.00%
Beta0.25
50-Day Avg2.63
200-Day Avg2.27

About

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Margaret Alexander
  • Employees23
  • HeadquartersHudson Commons, New York, NY, United States, 10001, USA
  • Websitehttps://www.ovidrx.com

Leadership

  • Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.Co-Founder & Executive Chairman · b. 1953
  • Ms. Margaret AlexanderCEO, President & Director · b. 1981
  • Mr. Jeffrey A. RonaAdvisor · b. 1968
  • Mr. Charles Ross Carter M.B.A., M.S.CFO, Principal Financial Officer, Principal Accounting Officer & Secretary · b. 1967
  • Dr. Zhong Zhong Ph.D.Chief Scientific Officer
  • Dr. Julia Tsai Ph.D.Senior Vice President of Clinical Development · b. 1975
  • Dr. Toshiya Nishi D.V.M.Head of Epilepsy Research
  • Dr. Manal Morsy M.B.A., M.D., PH.D.Chief Regulatory Officer
  • Ms. Victoria FortChief Strategy Officer
  • Dr. Petra Kaufmann M.D., M.S.Chief Medical Officer · b. 1966

Financials

Income Statement

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00000012.62M208.38M1.50M392.00K566.00K7.25M
Growth (%)-------+1551.57%-99.28%-73.91%+44.39%+1181.27%
Cost of Revenue011.78K56.51K80.31K141.73K255.00K--1.38M1.60M600.00K300.00K
Gross Profit0-11.78K-56.51K-80.31K-141.73K-255.00K12.62M208.38M1.50M392.00K566.00K6.95M
Gross Margin------100.00%100.00%100.00%100.00%100.00%95.86%
Operating Expense447.00K13.18M22.48M64.93M52.79M61.15M94.05M84.17M57.05M59.67M62.45M49.39M
Operating Income-447.00K-13.19M-22.54M-65.01M-52.93M-61.41M-81.43M124.21M-55.55M-59.28M-61.88M-42.44M
Operating Margin-------645.40%59.61%-3696.44%-15122.70%-10933.75%-585.20%
EBITDA-445.00K-13.18M-22.48M-64.93M-52.79M-61.15M-81.12M124.45M-54.17M-57.01M-57.77M-17.11M
EBITDA Margin-------642.96%59.72%-3604.50%-14544.13%-10207.07%-235.99%
Net Income-447.00K-13.16M-22.41M-64.81M-51.98M-59.26M-80.73M122.83M-51.41M-52.34M-26.43M-17.41M
Net Income Margin-------639.83%58.95%-3420.95%-13351.79%-4670.14%-240.13%
R&D105.38K6.61M9.59M49.97M33.79M42.16M63.42M46.94M24.62M28.59M36.77M25.58M
R&D as % of Total Revenue------502.63%22.53%1638.23%7292.86%6495.94%352.76%
Interest Expense000000046.79K2.76M---
Interest Expense % of Total Revenue------0.00%0.02%183.71%---

Balance Sheet

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.86M70.38M53.03M89.46M47.65M80.84M75.93M194.54M155.27M144.03M92.17M150.93M
Total Liabilities119.95K2.31M3.73M6.02M8.84M10.82M32.29M14.80M22.99M56.23M23.94M20.27M
Total Equity4.74M68.07M49.29M83.44M38.81M70.02M43.63M179.75M132.27M87.80M68.23M130.66M
Cash4.85M69.94M51.94M87.13M36.49M41.90M72.03M187.80M44.87M27.04M26.30M13.15M
Total Debt--------16.54M16.00M14.76M13.42M
Net Debt-4.85M-69.94M-51.94M-87.13M-36.49M-41.90M-72.03M-187.80M-28.33M-11.04M-11.55M266.00K

Cash Flow

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-261.28K-5.49M-17.80M-31.47M-45.56M-51.09M-51.58M118.61M-55.23M-45.78M-55.96M-38.33M
Investing Cash Flow-6.12K-56.33K-188.99K-47.39K-5.36M-30.04M34.65M-1.82M-87.88M-2.58M54.59M-49.85M
Financing Cash Flow6.73M70.64M-13.67K66.70M286.14K86.54M47.07M904.08K180.66K30.54M622.00K75.21M
Capital Expenditure1.78K56.33K188.99K47.39K352.02K244.04K390.68K189.41K1.42M137.46K71.00K0
Free Cash Flow-263.06K-5.54M-17.99M-31.52M-45.91M-51.33M-51.97M118.42M-56.65M-45.92M-56.03M-38.33M
Dividends Paid---0--------
FCF to OCF100.68%101.03%101.06%100.15%100.77%100.48%100.76%99.84%102.57%100.30%100.13%100.00%
Dividend Paid to FCF---0.00%--------

Earnings

Report DateJun 13, 2017Aug 10, 2017Nov 9, 2017Mar 29, 2018May 8, 2018Aug 9, 2018Nov 8, 2018Mar 7, 2019May 7, 2019Aug 7, 2019Nov 8, 2019Mar 11, 2020May 7, 2020Aug 10, 2020Nov 12, 2020Mar 15, 2021May 13, 2021Aug 16, 2021Nov 10, 2021Mar 15, 2022May 10, 2022Aug 9, 2022Nov 8, 2022Mar 13, 2023May 5, 2023Aug 4, 2023Nov 3, 2023Mar 8, 2024May 14, 2024Aug 13, 2024Nov 12, 2024Mar 6, 2025May 13, 2025Aug 13, 2025Nov 12, 2025Mar 16, 2026May 12, 2026Aug 13, 2026Nov 11, 2026
EPS Estimate-0.87-0.48-0.54-0.41-0.53-0.61-0.61-0.55-0.41-0.40-0.36-0.39-0.33-0.35-0.35-0.311.13-0.16-0.18-0.16-0.21-0.25-0.21-0.18-0.17-0.21-0.19-0.05-0.23-0.24-0.23-0.17-0.13-0.15-0.15-0.11-0.11-0.10-0.08
EPS Actual-3.48-0.57-0.38-0.45-0.54-0.53-0.53-0.52-0.46-0.34-0.43-0.35-0.37-0.41-0.28-0.342.53-0.23-0.17-0.10-0.20-0.21-0.17-0.16-0.19-0.18-0.16-0.22-0.170.12-0.20-0.13-0.14-0.06-0.170.06-0.12-0.08-
Surprise-300.00%-18.75%29.63%-9.76%-1.89%13.11%13.11%5.45%-12.20%15.00%-19.44%10.26%-12.12%-17.14%20.00%-9.68%123.89%-43.75%5.56%37.50%4.76%16.00%19.05%11.11%-11.76%14.29%15.79%-340.00%26.09%150.00%13.04%22.20%-7.69%60.00%-13.33%152.77%-9.09%20.00%-
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap468.71M
Enterprise Value399.19M
Trailing P/E0.00
Forward P/E1.79
PEG Ratio0.00
Price / Sales296.09
Price / Book2.40
EPS-0.21
Book Value1.14
Revenue (TTM)1.58M
Gross Profit (TTM)1.58M
EBITDA-57.97M
Profit Margin0.00%
Operating Margin-2100.68%
Return on Equity-25.96%
Return on Assets-23.46%
Shares Outstanding195.30M
Shares Float163.39M
Beta0.25
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 6 analystsTarget 5.92
  • Strong Buy
    5
  • Buy
    1

Ownership Breakdown

Institutions
80.42%
Insiders
6.72%
Retail / Other
12.86%

Top Institutional Holders

  • Eventide Asset Management, LLC
    11.81M6.05%
  • RA Capital Management, LLC
    10.71M5.49%
  • HHG PLC
    10.71M5.49%
  • Affinity Asset Advisors, LLC
    10.14M5.19%
  • Adage Capital Partners Gp LLC
    6.16M3.16%
  • Federated Hermes Inc
    5.95M3.05%
  • Balyasny Asset Management LLC
    5.53M2.83%
  • Vanguard Capital Management, LLC
    5.26M2.69%
  • ADAR1 Capital Management LLC
    4.54M2.33%
  • Ikarian Capital, LLC
    2.89M1.48%
  • Susquehanna International Group, LLP
    1.95M1.00%
  • Sphera Funds Management Ltd.
    1.62M0.83%
  • BlackRock Inc
    1.53M0.79%
  • Point72 Asset Management, L.P.
    1.32M0.68%

Top Fund Holders

  • Eventide Healthcare & Life Sciences I
    11.81M6.05%
  • Federated Hermes Kaufmann Small Cap A
    5.95M3.05%
  • Vanguard MStar Total Stk Mkt Idx Invest
    5.65M2.89%
  • State Street® SPDR® S&P® Biotech ETF
    5.19M2.66%
  • iShares Russell 2000 ETF
    3.83M1.96%
  • Fidelity Small Cap Index
    1.66M0.85%